Please login to the form below

Not currently logged in
Email:
Password:

Jorge Mestre-Ferrandiz to lead Office of Health Economics' consultancy division

Takes on newly-created position as OHE Consulting seeks expansion

Jorge Mestre-Ferrandiz - Office Health EconomicsThe Office of Health Economics (OHE) has appointed Dr Jorge Mestre-Ferrandiz as the first director of OHE Consulting – the organisation's consultancy division.

Mestre-Ferrandiz will lead the division's efforts to provide research-led consultancy in the health and life sciences economics and policy as it attempts to win external funding as part of plans to expand its operations.

He is in the sixth year of his second spell with the OHE, having previously worked at the research firm from 2001 to 2005 before spending a year at Spanish pharmaceutical trade association Farmaindustria.

He moved back to UK-based OHE in 2006, however, rejoining as a senior economist. In his new role Mestre-Ferrandiz will be responsible for all aspects of the OHE's consultancy business, including marketing, business development and project management.

He will also continue to contribute to all other OHE activities, including advising the UK pharma body the ABPI, as well as conducting and publishing his own research.

Mestre-Ferrandiz said: “I am confident that our experienced and highly skilled team of health economists will be a great draw for those looking to further their understanding of the health and life-sciences landscape and I am pleased I will be still be contributing personally as an economist to on-going projects.”

OHE Consultancy was set up in 2002 as an offshoot of the 50-year old OHE, which is funded by research grants and consultancy revenues from sources such as the ABPI, Department of Health, National Institute of Health Research and Medical Research Council.

17th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
TVF Communications

At TVF we do things a bit differently – our in-house design and development teams work directly alongside our commercial...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics